SEARCH

SEARCH BY CITATION

References

  • 1
    Kopelman PG. Obesity as a medical problem. Nature 2000;404:63543.
  • 2
    Barsh GS, Farooqi IS, O’Rahilly S. Genetics of body-weight regulation. Nature 2000;404:64451.
  • 3
    Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:42532.
  • 4
    Friedman JM. Obesity in the new millennium. Nature 2000;404:6324.
  • 5
    Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996;382:2502.
  • 6
    Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995;83:126371.
  • 7
    Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997;387:9038.
  • 8
    Farooqi IS, Wangensteen T, Collins S, Kimber W, Matarese G, Keogh JM et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med 2007;356:23747.
  • 9
    Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999;341:87984.
  • 10
    Farooqi IS, Bullmore E, Keogh J, Gillard J, O’Rahilly S, Fletcher PC. Leptin regulates striatal regions and human eating behavior. Science 2007;317:1355.
  • 11
    Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002;110:1093103.
  • 12
    Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998;19:1557.
  • 13
    Krude H, Biebermann H, Schnabel D, Tansek MZ, Theunissen P, Mullis PE et al. Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10. J Clin Endocrinol Metab 2003;88:463340.
  • 14
    Farooqi IS, Drop S, Clements A, Keogh JM, Biernacka J, Lowenbein S et al. Heterozygosity for a POMC-null mutation and increased obesity risk in humans. Diabetes 2006;55:254953.
  • 15
    Lee YS, Challis BG, Thompson DA, Yeo GS, Keogh JM, Madonna ME et al. A POMC variant implicates beta-melanocyte-stimulating hormone in the control of human energy balance. Cell Metab 2006;3:13540.
  • 16
    Biebermann H, Castaneda TR, van Landeghem F, von Deimling A, Escher F, Brabant G et al. A role for beta-melanocyte-stimulating hormone in human body-weight regulation. Cell Metab 2006;3:14114612.
  • 17
    Creemers JW, Lee YS, Oliver RL, Bahceci M, Tuzcu A, Gokalp D et al. Mutations in the amino-terminal region of proopiomelanocortin (POMC) in patients with early-onset obesity impair POMC sorting to the regulated secretory pathway. J Clin Endocrinol Metab 2008;93:44949.
  • 18
    Farooqi IS, Yeo GS, Keogh JM, Aminian S, Jebb SA, Butler G et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 2000;106:2719.
  • 19
    Alharbi KK, Spanakis E, Tan K, Smith MJ, Aldahmesh MA, O’Dell SD et al. Prevalence and functionality of paucimorphic and private MC4R mutations in a large, unselected European British population, scanned by meltMADGE. Hum Mutat 2007;28:294302.
  • 20
    Stutzmann F, Tan K, Vatin V, Dina C, Jouret B, Tichet J et al. Prevalence of melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees. Diabetes 2008;57:25118.
  • 21
    Yeo GS, Lank EJ, Farooqi IS, Keogh J, Challis BG, O’Rahilly S. Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms. Hum Mol Genet 2003;12:56174.
  • 22
    Farooqi IS. The severely obese patient – a genetic work-up. Nat Clin Pract Endocrinol Metab 2006;2:1727.
  • 23
    Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O’Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 2003;348:108595.
  • 24
    Nogueiras R, Wiedmer P, Perez-Tilve D, Veyrat-Durebex C, Keogh JM, Sutton GM et al. The central melanocortin system directly controls peripheral lipid metabolism. J Clin Invest 2007;117:347588.
  • 25
    Martinelli CE, Keogh JM, Greenfield JR, Henning E, van der Klaauw AA, Blackwood A et al. Obesity due to Melanocortin 4 Receptor (MC4R) deficiency is associated with increased linear growth and final height, fasting hyperinsulinemia, and incompletely suppressed growth hormone secretion. J Clin Endocrinol Metab 2011;96:E1818.
  • 26
    Tallam LS, Stec DE, Willis MA, da Silva AA, Hall JE. Melanocortin-4 receptor-deficient mice are not hypertensive or salt-sensitive despite obesity, hyperinsulinemia, and hyperleptinemia. Hypertension 2005;46:32632.
  • 27
    Greenfield JR, Miller JW, Keogh JM, Henning E, Satterwhite JH, Cameron GS et al. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 2009;360:4452.
  • 28
    Gray J, Yeo GS, Cox JJ, Morton J, Adlam AL, Keogh JM et al. Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. Diabetes 2006;55:336671.
  • 29
    Yeo GS, Hung CCC, Rochford J, Keogh J, Gray J, Sivaramakrishnan S et al. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci 2004;7:11879.
  • 30
    Bochukova EG, Huang N, Keogh J, Henning E, Purmann C, Blaszczyk K et al. Large, rare chromosomal deletions associated with severe early-onset obesity. Nature 2010;463:66670.